NCT05644561 2026-02-19Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)Alexion Pharmaceuticals, Inc.Phase 3 Active not recruiting12 enrolled
NCT03920293 2024-05-28Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia GravisAlexion Pharmaceuticals, Inc.Phase 3 Completed175 enrolled 15 charts